PEPCLUB.me

Growth Hormone SupportSleepBody CompositionAnti-AgingArticlePremium

Ipamorelin

5mg Vial

9 July 2026Updated 29 August 2026

Ipamorelin

Overview Research13

Mechanism Protocols Safety Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Ipamorelin.

Create free account Member login

Full range of benefits for Ipamorelin

Stimulates growth hormone (GH) release

Increases GH pulse amplitude and frequency

Can raise IGF-1 levels via GH-mediated pathways

Supports preservation and gain of lean muscle mass

May assist reduction of body fat and improve composition

Supports tissue repair and collagen synthesis

May promote bone formation via the GH/IGF‑1 axis

Selective GH stimulation with minimal cortisol/ACTH rise

May enhance recovery and exercise tolerance through GH effects

Can augment nocturnal GH secretion linked to sleep cycles

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

13 Published Studies

Scientific literature related to Ipamorelin and its potential applications.

Abstract analysed

The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.

In tilapia, 21-day treatment with ipamorelin acetate increased food intake and markers of spermatogenesis (cell counts and testis morphology), raised serum LH and 11-ketotestosterone, and increased testicular androgen receptor expression, suggesting ghrelin agonist stimulation of the hypothalamic-pituitary-testicular axis in this species.

Reproductive endocrinologyFish physiology and aquacultureGhrelin signaling and pharmacology+1 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.1016/j.anireprosci.2024.107550

Published

2024

Full text analysed

Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.

Intravenous ipamorelin (peripherally restricted ghrelin receptor agonist) reduced experimentally induced acute visceral and secondary somatic hypersensitivity in male rats; effects were blocked by a selective ghrelin receptor antagonist, supporting a receptor-mediated mechanism.

Peripheral ghrelin receptor pharmacologyVisceral pain mechanisms and therapeuticsViscero-somatic convergence and peripheral modulation+1 more

Relevance

75%

Source

Europe PMC, PubMed

DOI: 10.2147/jep.s249747

Published

2020

Abstract analysed

Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor.

Among a panel of peptidic and peptidomimetic growth hormone secretagogues (including ipamorelin), a peptidomimetic scaffold G-7039 was identified as most suitable for 18F radiolabelling and yielded a PET probe with good radiochemical characteristics; no specific experimental results for ipamorelin are reported in the abstract.

PET probe developmentGhrelin receptor (GHS-R1a) imagingPeptidomimetic ligand design and radiochemistry+1 more

Relevance

75%

Source

Europe PMC, PubMed

DOI: 10.1016/j.ejmech.2018.08.062

Published

2018

Abstract analysed

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.

In ferrets, peripheral administration of anamorelin or ipamorelin reduced cisplatin-associated weight loss in the delayed phase (~24% reduction). Anamorelin strongly inhibited ileum contractions in vitro and, when administered centrally, reduced acute emesis and improved acute-phase food and water intake, suggesting a central anti-emetic mechanism requiring brain access.

Anti-emesis mechanisms of ghrelin mimeticsCachexia/weight loss mitigation in chemotherapy modelsCentral versus peripheral mechanisms of GHSR1a agonists+1 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.1016/j.physbeh.2024.114644

Published

2024

Full text analysed

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

Ipamorelin is a selective GHSR-1a agonist that stimulates GH release; preclinical rodent studies show improved gastric emptying and increased early weight and adiposity, and a multicenter placebo-controlled human trial in bowel resection patients did not show significant benefit on primary GI recovery endpoints. Evidence for use in hypogonadal men or for improving body composition in humans is limited.

Randomized controlled trials of ipamorelin in hypogonadal men assessing body composition, GH/IGF-1 response, and metabolic endpointsLongitudinal safety studies in humans to detect potential adverse effects with chronic useMechanistic human studies on ipamorelin's effects on appetite, leptin, and adiposity+2 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.21037/tau.2019.11.30

Published

2020

Full text analysed

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

Ipamorelin is a GHRP-class growth-hormone secretagogue that increases GH secretion in humans with generally favourable short-term tolerability in limited phase I/development studies, but there is no robust clinical trial evidence that it improves body composition or performance, and long-term safety (including theoretical IGF-1–related mitogenic risks) is uncharacterised.

Randomized controlled trials evaluating ipamorelin effects on body composition, strength, and performance endpoints in relevant populations.Long-term safety studies tracking endocrine, metabolic, and malignancy outcomes after chronic or repeated ipamorelin exposure.Pharmacokinetic/pharmacodynamic studies clarifying dose–response relationships for GH and downstream IGF-1 in repeated-dosing regimens.+2 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.3389/fendo.2026.1822475

Published

2026

Abstract analysed

Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

For ipamorelin (and the other emerging peptides reviewed), promising effects in animal models have not been substantiated by robust human trials; human evidence is limited and heterogeneous and safety concerns have been reported for some peptides.

Well-designed, controlled human clinical trials for each peptide (including ipamorelin) assessing efficacy for musculoskeletal recovery.Standardized dosing and route-of-administration studies.Comprehensive safety and adverse event monitoring in humans, including cardiovascular and metabolic endpoints.+1 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.1177/03635465261464420

Published

2026

Abstract analysed

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Ipamorelin (reported in combination with CJC-1295) has shown improved muscle strength in murine models, but there is no supporting human orthopaedic evidence or reported safety data in the reviewed literature; overall clinical evidence is very limited.

Human clinical trials assessing efficacy of ipamorelin (alone and with CJC-1295) for musculoskeletal/orthopaedic conditionsSafety and tolerability studies of ipamorelin in human subjectsDose-ranging and treatment regimen optimization for ipamorelin+1 more

Relevance

82%

Source

Europe PMC, PubMed

DOI: 10.1177/03635465251357593

Published

2026

Full text analysed

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Ipamorelin is described as a selective ghrelin receptor agonist and GH secretagogue that may promote anabolic GH/IGF-1 signaling relevant to muscle and cartilage repair, but orthopaedic-specific clinical evidence is lacking and current support is based on mechanistic and preclinical rationale rather than randomized human trials.

Randomized, placebo-controlled trials of ipamorelin (alone and combined with CJC-1295) for orthopaedic endpoints (pain, function, healing metrics).Standardization of dosing regimens, routes, and schedules for ipamorelin in musculoskeletal applications.Safety monitoring studies focusing on endocrine effects, immunogenicity, and long-term outcomes in orthopaedic patients.+2 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.5435/jaaosglobal-d-25-00236

Published

2026

Abstract analysed

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

The review highlights increasing use of peptides (including ipamorelin) in sports medicine, notes favorable preclinical tissue-repair and metabolic findings for many unapproved peptides, but emphasizes scarce rigorous human safety data and the potential for serious harm from gray-market compounds.

Rigorous human clinical trials assessing safety and efficacy of ipamorelin and other peptides for musculoskeletal injuries and performancePost-market surveillance and regulatory oversight of peptides marketed directly to patientsMechanistic studies in humans to translate favorable animal tissue-repair findings+1 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.1007/s40279-026-02437-0

Published

2026